| scholarly article | Q13442814 |
| P50 | author | Regina Goetz | Q57078008 |
| Jyothsna Gattineni | Q91669992 | ||
| Michel Baum | Q93056786 | ||
| Moosa Mohammadi | Q37382162 | ||
| P2093 | author name string | Michael L Robinson | |
| Vangipuram Dwarakanath | |||
| Carlton Bates | |||
| Katherine Twombley | |||
| P2860 | cites work | Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity | Q22254157 |
| Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization | Q24290400 | ||
| Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 | Q24290481 | ||
| A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium | Q24308202 | ||
| FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis | Q24319751 | ||
| Fibroblast growth factors | Q24542507 | ||
| Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia | Q24623628 | ||
| Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family | Q24676527 | ||
| Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members | Q24683254 | ||
| Cell signaling by receptor tyrosine kinases | Q27860474 | ||
| Fibroblast growth factors, their receptors and signaling | Q28140520 | ||
| Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway | Q28198276 | ||
| Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23 | Q28209679 | ||
| Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro | Q28240791 | ||
| 25-Hydroxycholecalciferol-1-hydroxylase. Subcellular location and properties | Q28241509 | ||
| Klotho converts canonical FGF receptor into a specific receptor for FGF23 | Q28272505 | ||
| Role of glucocorticoids in the maturation of the rat renal Na+/H+ antiporter (NHE3) | Q28367625 | ||
| Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice | Q28507303 | ||
| FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung | Q28508008 | ||
| Role of fibroblast growth factor receptors 1 and 2 in the metanephric mesenchyme | Q28511352 | ||
| Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction | Q28513556 | ||
| The parathyroid is a target organ for FGF23 in rats | Q28572613 | ||
| Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type-II Na/Pi transporter | Q28575122 | ||
| Regulation of fibroblast growth factor-23 signaling by klotho | Q28587100 | ||
| Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism | Q29620323 | ||
| Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation | Q33938586 | ||
| Claudins 6, 9, and 13 are developmentally expressed renal tight junction proteins | Q34041051 | ||
| FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. | Q54733425 | ||
| DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. | Q54943458 | ||
| Identification of 1,25-Dihydroxycholecalciferol, a New Kidney Hormone controlling Calcium Metabolism | Q59054519 | ||
| Unique Biosynthesis by Kidney of a Biologically Active Vitamin D Metabolite | Q59089758 | ||
| Fibroblast growth factor receptors and their ligands in the adult rat kidney | Q60923181 | ||
| Phosphate transport in the proximal convolution of the rat kidney. I. Tubular heterogeneity, effect of parathyroid hormone in acute and chronic parathyroidectomized animals and effect of phosphate diet | Q67014466 | ||
| Studies on calciferol metabolism. I. Production of vitamin D metabolite 4B from 25-OH-cholecalciferol by kidney homogenates | Q68622590 | ||
| fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation | Q71989880 | ||
| Murine FGFR-1 is required for early postimplantation growth and axial organization | Q71989885 | ||
| Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia | Q72407098 | ||
| Tumor-induced osteomalacia--unveiling a new hormone | Q72407106 | ||
| Insertion of Cre into the Pax3 locus creates a new allele of Splotch and identifies unexpected Pax3 derivatives | Q81729304 | ||
| Effects of thyroid hormone on the neonatal renal cortical Na+/H+ antiporter | Q34041347 | ||
| Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23 | Q34075026 | ||
| Renal phosphate transport: inhomogeneity of local proximal transport rates and sodium dependence | Q34102395 | ||
| FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting | Q34227442 | ||
| Receptor for acidic fibroblast growth factor is related to the tyrosine kinase encoded by the fms-like gene (FLG). | Q34318542 | ||
| Activating mutations of the stimulatory G protein in the McCune-Albright syndrome | Q34981177 | ||
| Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction | Q35229509 | ||
| Complexity of FGF receptors: genetic basis for structural diversity and functional specificity | Q35595596 | ||
| The phosphatonin pathway: new insights in phosphate homeostasis | Q35607596 | ||
| Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. | Q35728669 | ||
| Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development | Q36064260 | ||
| Structural basis for fibroblast growth factor receptor activation | Q36111391 | ||
| Role of prostaglandins in the pathogenesis of X-linked hypophosphatemia. | Q36487782 | ||
| FGFR3 and FGFR4 do not mediate renal effects of FGF23. | Q36985772 | ||
| Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome | Q37046536 | ||
| Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3 | Q37178523 | ||
| Endocrine FGFs and Klothos: emerging concepts | Q37240464 | ||
| Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. | Q40008486 | ||
| Regulation of the metabolism of vitamin D. | Q40284790 | ||
| Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. | Q40475013 | ||
| Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders | Q40530218 | ||
| Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. | Q40864479 | ||
| 5'-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. | Q42051203 | ||
| Role of the vitamin D receptor in FGF23 action on phosphate metabolism | Q42156385 | ||
| Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. | Q42493065 | ||
| cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone | Q42638660 | ||
| Increased thymus- and decreased parathyroid-fated organ domains in Splotch mutant embryos | Q43180159 | ||
| Site of 1,25(OH)2 vitamin D3 synthesis in the kidney | Q43812165 | ||
| Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice | Q44142771 | ||
| Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia | Q44203982 | ||
| Neural crest expression of Cre recombinase directed by the proximal Pax3 promoter in transgenic mice | Q44253400 | ||
| Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia | Q44414604 | ||
| Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis | Q44779387 | ||
| Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules | Q46654185 | ||
| Pathogenic role of Fgf23 in Hyp mice. | Q46921328 | ||
| Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells | Q46970328 | ||
| Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets | Q48049188 | ||
| FGF signaling through FGFR1 is required for olfactory bulb morphogenesis | Q48394629 | ||
| Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. | Q49042849 | ||
| Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. | Q53964449 | ||
| Vitamin D metabolism: the role of kidney tissue. | Q54633053 | ||
| P433 | issue | 2 | |
| P304 | page(s) | F282-91 | |
| P577 | publication date | 2009-06-10 | |
| P1433 | published in | American Journal of Physiology - Renal Physiology | Q2610177 |
| P1476 | title | FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. | |
| P478 | volume | 297 |
| Q38327140 | 1,25-Dihydroxyvitamin D(3) and extracellular inorganic phosphate activate mitogen-activated protein kinase pathway through fibroblast growth factor 23 contributing to hypertrophy and mineralization in osteoarthritic chondrocytes |
| Q93105582 | A G protein-coupled, IP3/protein kinase C pathway controlling the synthesis of phosphaturic hormone FGF23 |
| Q37777967 | A comprehensive analysis of gene expression profiles in distal parts of the mouse renal tubule. |
| Q51308109 | A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia. |
| Q88915341 | A model of calcium transport and regulation in the proximal tubule |
| Q36770978 | Activation of a non-cAMP/PKA signaling pathway downstream of the PTH/PTHrP receptor is essential for a sustained hypophosphatemic response to PTH infusion in male mice |
| Q39354503 | Additive effects of fibroblast growth factor 23 neutralization and dietary phytase on chick calcium and phosphorus metabolism |
| Q34597741 | Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases |
| Q51709073 | Antibody to fibroblast growth factor 23-peptide reduces excreta phosphorus of laying hens. |
| Q34603360 | Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia |
| Q47989110 | Biology of Fibroblast Growth Factor 23: From Physiology to Pathology |
| Q39666379 | Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells |
| Q90469042 | C-FGF23 peptide alleviates hypoferremia during acute inflammation |
| Q35996158 | Calcium Extrusion Pump PMCA4: A New Player in Renal Calcium Handling? |
| Q48038085 | Calcium Homeostasis in Health and in Kidney Disease |
| Q37244863 | Can features of phosphate toxicity appear in normophosphatemia? |
| Q38977291 | Cardiac actions of fibroblast growth factor 23. |
| Q27024043 | Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease |
| Q88548458 | Central role of the proximal tubular αKlotho/FGF receptor complex in FGF23-regulated phosphate and vitamin D metabolism |
| Q85025638 | Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation |
| Q90521275 | Claudin-12 Knockout Mice Demonstrate Reduced Proximal Tubule Calcium Permeability |
| Q90655716 | Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy |
| Q37824821 | Clinical practice. Fibroblast growth factor (FGF)23: a new hormone |
| Q34718202 | Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype |
| Q35912924 | Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport. |
| Q60668167 | Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy |
| Q38757058 | Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport |
| Q36217292 | Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor |
| Q37801814 | Disorders of phosphorus homeostasis |
| Q28085476 | Dysregulation of phosphate metabolism and conditions associated with phosphate toxicity |
| Q47221759 | Effect of Osteocyte-Ablation on Inorganic Phosphate Metabolism: Analysis of Bone-Kidney-Gut Axis. |
| Q50049087 | Effect of different concentrations of dietary P and Ca on plasma inorganic P and urinary P excretion using noncolostomized and colostomized broilers |
| Q89821664 | Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis |
| Q42370104 | Effects of phospho- and calciotropic hormones on electrolyte transport in the proximal tubule. |
| Q55344755 | Elevated FGF23 Levels in Mice Lacking the Thiazide-Sensitive NaCl cotransporter (NCC). |
| Q50692928 | Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice. |
| Q57298169 | Emerging role of precision medicine in biliary tract cancers |
| Q39168168 | Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansi |
| Q36923686 | Excessive fructose intake causes 1,25-(OH)(2)D(3)-dependent inhibition of intestinal and renal calcium transport in growing rats |
| Q35156017 | FGF-23: More than a regulator of renal phosphate handling? |
| Q98906651 | FGF/FGFR signaling in health and disease |
| Q54960612 | FGF23 Actions on Target Tissues-With and Without Klotho. |
| Q42256983 | FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway |
| Q26851904 | FGF23 and Phosphate Wasting Disorders |
| Q36750178 | FGF23 as a calciotropic hormone |
| Q90101217 | FGF23 at the crossroads of phosphate, iron economy and erythropoiesis |
| Q34130840 | FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. |
| Q90258788 | FGF23 in Cardiovascular Disease: Innocent Bystander or Active Mediator? |
| Q36639867 | FGF23 production by osteocytes |
| Q89357401 | FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study |
| Q45233297 | Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. |
| Q35690579 | Fibroblast growth factor 23 and acute kidney injury |
| Q84083027 | Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease |
| Q54534133 | Fibroblast growth factor-23 abolishes 1,25-dihydroxyvitamin D₃-enhanced duodenal calcium transport in male mice. |
| Q92090617 | First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia |
| Q28086929 | Functional diversity of fibroblast growth factors in bone formation |
| Q41907618 | Functional heterogeneity of osteocytes in FGF23 production: the possible involvement of DMP1 as a direct negative regulator. |
| Q26998955 | Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers |
| Q27022049 | Genetic disorders of phosphate regulation |
| Q38102603 | Hyperphosphataemia: treatment options |
| Q89161363 | Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature |
| Q55413743 | Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23. |
| Q35837789 | Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients |
| Q21092419 | Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice |
| Q52720297 | Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH. |
| Q104064562 | Increased expression of fibroblast growth factor 23 is the signature of a deteriorated Ca/P balance in ageing laying hens |
| Q38189644 | Inherited disorders of calcium and phosphate metabolism |
| Q36592828 | Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo |
| Q53562681 | Intestinal Depletion of NaPi-IIb/Slc34a2 in Mice: Renal and Hormonal Adaptation. |
| Q38185277 | Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond? |
| Q90408770 | Involvement of estrogen in phosphorus-induced nephrocalcinosis through fibroblast growth factor 23 |
| Q85670159 | Key role of the kidney in the regulation of fibroblast growth factor 23 |
| Q47350767 | Klotho & Activin A in kidney injury Plasma Klotho is maintained in unilateral obstruction despite no upregulation of Klotho biosynthesis in contralateral kidney |
| Q38732756 | Klotho Lacks an FGF23-Independent Role in Mineral Homeostasis |
| Q37858474 | Klotho: a novel regulator of calcium and phosphorus homeostasis |
| Q46307080 | Maternally derived anti-fibroblast growth factor 23 antibody as new tool to reduce phosphorus requirement of chicks |
| Q89442831 | Mechanisms and Regulation of Intestinal Phosphate Absorption |
| Q92548203 | Mechanisms of phosphate transport |
| Q37406418 | Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia |
| Q53005827 | Muscle-Bone Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches to Treat Musculoskeletal Pathologies. |
| Q57796697 | Non-renal-Related Mechanisms of FGF23 Pathophysiology |
| Q35877889 | Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q37958204 | Osteocytes: central conductors of bone biology in normal and pathological conditions |
| Q38804461 | PTH and Vitamin D. |
| Q39122744 | Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction |
| Q55221465 | Paracrine Effects of FGF23 on the Heart. |
| Q34480642 | Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. |
| Q47403256 | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. |
| Q24610674 | Phosphate and FGF-23 |
| Q37763810 | Phosphate homeostasis and the renal-gastrointestinal axis |
| Q35059905 | Phosphate toxicity: new insights into an old problem |
| Q42726284 | Phosphorous dysregulation induced by MEK small molecule inhibitors in the rat involves blockade of FGF-23 signaling in the kidney |
| Q89964416 | Phosphorus Restriction Changes the Expression of Fibroblast Growth Factor 23 and Its Receptors in Laying Hens |
| Q55375521 | Physiological Actions of Fibroblast Growth Factor-23. |
| Q54139850 | Pleiotropic Actions of FGF23. |
| Q40654330 | Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia |
| Q37407740 | Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children |
| Q35829300 | Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. |
| Q34124765 | Proximal tubule function and response to acidosis |
| Q37679946 | Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia |
| Q26860470 | Regulation and function of the FGF23/klotho endocrine pathways |
| Q36649088 | Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. |
| Q35151453 | Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism |
| Q28592945 | Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4 |
| Q28506271 | Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4 |
| Q37922621 | Regulation of target gene expression by the vitamin D receptor - an update on mechanisms |
| Q36364305 | Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women |
| Q59136491 | Renal ADAM10 and 17: Their Physiological and Medical Meanings |
| Q34962806 | Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor |
| Q34568797 | Renal phosphate wasting in the absence of adenylyl cyclase 6 |
| Q85036605 | Rickets |
| Q55026099 | Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy. |
| Q90102237 | Role of αKlotho and FGF23 in regulation of type II Na-dependent phosphate co-transporters |
| Q64118060 | Roles of Phosphate in Skeleton |
| Q39220825 | Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. |
| Q35525893 | Selection of a novel FGF23-binding peptide antagonizing the inhibitory effect of FGF23 on phosphate uptake |
| Q58711341 | Serum phosphate and phosphate-regulatory hormones in COPD patients |
| Q41313413 | Serum sTWEAK and FGF-23 Levels in Hemodialysis and Renal Transplant Patients |
| Q38855334 | Shedding of klotho by ADAMs in the kidney |
| Q38730488 | Shedding quantitative fluorescence light on novel regulatory mechanisms in skeletal biomedicine and biodentistry |
| Q38152465 | Significance of the anti-aging protein Klotho |
| Q37730368 | Switch in FGFR3 and -4 expression profile during human renal development may account for transient hypercalcemia in patients with Sotos syndrome due to 5q35 microdeletions |
| Q38821293 | The Cerebrovascular-Chronic Kidney Disease Connection: Perspectives and Mechanisms |
| Q24625902 | The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis |
| Q36201091 | The G protein α subunit variant XLαs promotes inositol 1,4,5-trisphosphate signaling and mediates the renal actions of parathyroid hormone in vivo. |
| Q92959917 | The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia |
| Q38183365 | The Roles of Fibroblast Growth Factor (FGF)-23, α-Klotho and Furin Protease in Calcium and Phosphate Homeostasis : A Mini-Review |
| Q34221238 | The changing face of hypophosphatemic disorders in the FGF-23 era |
| Q39160284 | The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells |
| Q38053246 | The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications |
| Q37203605 | The osteocyte: an endocrine cell ... and more |
| Q37771349 | The phosphate regulating hormone fibroblast growth factor-23. |
| Q37493998 | The rachitic tooth |
| Q57801450 | The role of klotho in chronic kidney disease |
| Q36928572 | The structural biology of the FGF19 subfamily |
| Q38732752 | Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption |
| Q42529430 | Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372 |
| Q33579283 | Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature |
| Q59100578 | Vascular calcification and renal bone disorders |
| Q50001744 | α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling |
Search more.